Chicago, IL - The 2014 ASCO Annual Meeting - "Maurice Perol, MDat Abstract #LBA8006^: ""REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy,"" Lung Cancer (Non-small Cell Metastatic) Oral Abstract Session Keyword: AM14_Maurice_Perol" at the American Society of Clinical Oncology Annual Meeting here today, Monday June 2, 2014. More than 30,000 physicians, researchers, health care professionals, cancer survivors and patient advocates are expected to attend the 50th Anniversary meeting at the McCormick Convention Center. The Annual Meeting highlights the latest findings in all major areas of oncology from basic through clinical and epidemiological studies. Photo by © ASCO/Scott Morgan 2014 Technical Questions: todd@medmeetingimages.com
Chicago, IL - The 2014 ASCO Annual Meeting - "Antoni Ribas, MD, PhDat Abstract #LBA9000^: ""Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL),"" Melanoma/Skin Cancers Oral Abstract Session Keyword: AM14_Antoni_Ribas" at the American Society of Clinical Oncology Annual Meeting here today, Monday June 2, 2014. More than 30,000 physicians, researchers, health care professionals, cancer survivors and patient advocates are expected to attend the 50th Anniversary meeting at the McCormick Convention Center. The Annual Meeting highlights the latest findings in all major areas of oncology from basic through clinical and epidemiological studies. Photo by © ASCO/Todd Buchanan 2014 Technical Questions: todd@medmeetingimages.com
